CYP3a5 Genetic Polymorphism in Chinese Population With Renal Transplantation: A Meta-Analysis Review

Cao, Peng; Zhang, Feilong; Zhang, Jian-Dong; Zheng, Xiang; Sun, Zejia; Yu, Baozhong; Wang, Wei

doi:10.1016/j.transproceed.2021.10.031

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of the 498 patients included in eight studies, the percentage of CYP3A5*3 expressors in the Chinese population was found to be 67.07%. This finding aligns with a previous study, which also reported a high mutation rate of 72.7% for the CYP3A5*3 genotype in the Chinese population ( Cao et al, 2022 ). The meta-analysis revealed that tacrolimus blood concentrations of CYP3A5 expressers were significantly lower than those of CYP3A5 non-expressers in Chinese MN patients.…”

Section: Discussionsupporting

confidence: 93%

Meta-analysis of the effects of CYP3A5*3 gene polymorphisms on tacrolimus blood concentration and effectiveness in Chinese patients with membranous nephropathy

Dai,

Yuan,

Chai

2024

Front. Pharmacol.

View full text Add to dashboard Cite

ObjectiveThe study aimed to systematically evaluate the relationship between CYP3A5*3 gene polymorphisms and the blood concentration and effectiveness of tacrolimus (TAC) in patients with membranous nephropathy (MN).MethodsPubMed, Cochrane Library, Embase, Web of Science, China Biomedical, China National Knowledge Infrastructure, Wanfang, Vipshop, ReadShow, Clinical Trials Registry, and other databases were searched. Studies on the relationship between CYP3A5*3 gene polymorphism and TAC blood concentration in MN patients were collected, and meta-analysis was performed using Stata 16 software. ResultsA total of eight publications were included in the study, including 498 MN patients. CYP3A5*3 gene polymorphisms are associated with tacrolimus blood levels in patients with MN. The results of the relationship between CYP3A5*3 genotype polymorphisms and tacrolimus blood trough concentrations of the AA + AG genotype were lower than those of the GG genotype at ≤1 month [WMD = −2.08, 95% CI (−2.57, −1.59), p < 0.001] and 1–6 months [WMD = −0.63, 95% CI (−0.98, −0.27), p < 0.001]; however, they were not statistically significant at ≥6 months (p = 0.211). Furthermore, the subgroup analysis revealed that the dose-adjusted concentration of tacrolimus (C0/D) of the AA + AG genotype was lower than that of the GG genotype at ≤1 month [SMD = −1.93, 95% CI (−2.79, −1.08), p < 0.001], 1–6 months [SMD = −2.25, 95% CI (−2.71, −1.79), p < 0.001], and ≥6 months [SMD = −2.36, 95% CI (−2.86, −1.86), p < 0.001]. In addition, there was no statistically significant difference in effectiveness between the two groups at 3, 6, and 12 months of TAC administration (p > 0.05).ConclusionSerum TAC concentrations in MN patients were correlated with CYP3A5*3 genotype polymorphisms. Detection of the CYP3A5*3 genotype before the administration of TAC may provide some clinical value for optimizing the treatment of MN patients.Systematic Review Registration:https://inplasy.com/, identifier [INPLASY202430083].

show abstract

Section: Discussionsupporting

confidence: 93%